Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Nov 15;3(11):100823.
doi: 10.1016/j.xcrm.2022.100823.

Identifying inflammatory phenotypes to target mechanism-specific treatments in sepsis

Hernando Gómez  1 , Renee R Anderko  2 , Joseph A Carcillo  3
Affiliations
Comment

Identifying inflammatory phenotypes to target mechanism-specific treatments in sepsis

Hernando Gómez et al. Cell Rep Med. .

Abstract

A clinical trial by Leventogiannis et al.1 suggests that ferritin and HLA-DR monocyte receptor expression can identify septic patients with macrophage-activation-like syndrome (MALS), or immunoparalysis, and that targeting IL-1ra treatment with this strategy may improve outcomes.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests H.G. discloses consulting agreements with Novartis and Trilinear Bioventures.

Comment on

  • Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial.
    Leventogiannis K, Kyriazopoulou E, Antonakos N, Kotsaki A, Tsangaris I, Markopoulou D, Grondman I, Rovina N, Theodorou V, Antoniadou E, Koutsodimitropoulos I, Dalekos G, Vlachogianni G, Akinosoglou K, Koulouras V, Komnos A, Kontopoulou T, Prekates A, Koutsoukou A, van der Meer JWM, Dimopoulos G, Kyprianou M, Netea MG, Giamarellos-Bourboulis EJ. Leventogiannis K, et al. Cell Rep Med. 2022 Nov 15;3(11):100817. doi: 10.1016/j.xcrm.2022.100817. Cell Rep Med. 2022. PMID: 36384100 Free PMC article. Clinical Trial.

References

    1. Leventogiannis K.,K.E., Antonakos N., Kotsaki A., Tsangaris I., Markopoulou D., Grondman I., Rovina N., Theodorou V., Antoniadou E., Koutsodimitropoulos I., et al. Towards personalized immunotherapy in sepsis: the PROVIDE randomized clinical trial. Cell Reports Medicine. 2022;3:1–2. - PMC - PubMed
    1. Scicluna B.P., van Vught L.A., Zwinderman A.H., Wiewel M.A., Davenport E.E., Burnham K.L., Nürnberg P., Schultz M.J., Horn J., Cremer O.L., et al. Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. The Lancet. Respiratory medicine. 2017;5:816–826. doi: 10.1016/S2213-2600(17)30294-1. - DOI - PubMed
    1. Li H., Markal A., Balch J.A., Loftus T.J., Efron P.A., Ozrazgat-Baslanti T., Bihorac A. Methods for phenotyping Adult patients in sepsis and septic shock: a scoping review. Crit Care Explor. 2022;4 doi: 10.1097/CCE.0000000000000672. - DOI - PMC - PubMed
    1. Davenport E.E., Burnham K.L., Radhakrishnan J., Humburg P., Hutton P., Mills T.C., Rautanen A., Gordon A.C., Garrard C., Hill A.V.S., et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. The Lancet. Respiratory medicine. 2016;4:259–271. doi: 10.1016/S2213-2600(16)00046-1. - DOI - PMC - PubMed
    1. Shakoory B., Carcillo J.A., Chatham W.W., Amdur R.L., Zhao H., Dinarello C.A., Cron R.Q., Opal S.M. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: Reanalysis of a prior phase III trial. Crit. Care Med. 2016;44:275–281. doi: 10.1097/CCM.0000000000001402. - DOI - PMC - PubMed

Substances